Future studies employing hypoxic tumor cell lines, in vivo cancer or ischemia models, and clinical samples will be essential to determine the broader physiological and pathological relevance of HMGB1 K177 lactylation‐mediated SG formation—and to explore its potential as a therapeutic target in hypoxia‐associated diseases. The gene discussed is HMGB1; the disease is neoplasm.